Supplier News: Axplora, Experic, Recipharm & More
The latest from CDMOs, CMOs, and suppliers featuring Recipharm, Axplora, Experic, MGS and DFE Pharma.
Chemicals/Chemical API Manufacturing
* Scinai Acquires Recipharm Israel
Formulation Development/Drug Product Manufacturing
* Axplora To Expand Lyophilization Capacity for ADCs
* DFE Pharma Launches Continuous Manufacturing Platform
* Recipharm Expanding High-Potency Capabilities for Solid Dosage Products
Packaging
* MGS Opens New Drug-Device Mfg Facility
Appointments
* Experic Appoints New CEO
Chemicals/Chemical API Manufacturing
Scinai Acquires Recipharm Israel
Scinai Immunotherapeutics, a bio/pharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a CDMO business, has acquired 100% of the shares of Recipharm Israel, which operates Recipharm’s active pharmaceutical ingredient (API) development and manufacturing site in Yavne, Israel. The cGMP manufacturing site provides early chemistry development and small-scale API manufacturing services supporting clinical-stage programs. The companies also entered into a long-term strategic commercial collaboration.
Source: Scinai Immunotherapeutics and Recipharm
Formulation Development/Drug Product Manufacturing
Axplora To Expand Lyophilization Capacity for ADCs
Axplora, a CDMO of small-molecule active pharmaceuticals ingredients (APIs), intermediates, and antibody drug conjugates (ADCs), and a provider of industrial chromatography services, has announced a multi-million-euro investment to expand lyophilization (freeze-drying) capabilities at its Le Mans, France, site. The company is adding onsite commercial lyophilization to the R&D capabilities already in place to provide for the isolation and handling of complex payload and linker intermediates. The new lyophilization capabilities are expected to come online in 2027.
The expansion forms part of Axplora’s continued multi-year EUR 30 million ($35 million) investment program at its Le Mans site by building on recent payload and capacity expansions to support ADCs. It also forms part of Axplora’s broader investment of more than EUR 100 million ($117 million) invested across the company in 2025.
Source: Axplora
DFE Pharma Launches Continuous Manufacturing Platform
DFE Pharma, a manufacturer of excipients, has announced the launch of a continuous manufacturing (CM) platform, in collaboration with Gericke, a company providing feeding, blending, and powder processing equipment, to support pharmaceutical companies in formulation development, optimization, and lifecycle management of CM processes.
As part of the CM platform, DFE Pharma has invested in continuous manufacturing capability at its C2F Center of Excellence in Hyderabad, India, featuring a Gericke formulation skid. This formulation skid, with modular feeding and blending options, is placed in a non-GMP environment to enable fast iterations and practical assessment and optimization without disrupting existing GMP manufacturing or requiring upfront infrastructure investment. The equipment gives pharmaceutical companies the opportunity to experience how continuous feeding and blending operate in practice, test formulation strategies using CM-ready materials, and learn how evaluation data translates directly into real world implementation.
Source: DFE Pharma
Recipharm Expanding High-Potency Capabilities for Solid Dosage Products
Recipharm has announced an expansion in its high-potency oral solid-dose capabilities at its site in Leganés, Spain. The new high-potency clinical and pilot capabilities are scheduled to be operational by the end of the year (2026). The expansion will support (1) high-potency Phase III clinical programs, including process transfer and optimization; (2) high-potency pilot-scale GMP projects; and (3) small-scale commercial production (10 kg+), particularly suited for products such as pediatrics or orphan drugs where high-potency containment is required.
Source: Recipharm
Packaging
MGS Opens New Drug-Delivery Device Mfg Facility
MGS, a CDMO of drug-delivery device, has opened a new manufacturing facility in Richfield, Wisconsin. The 300,000-square-foot operation was developed to support a global pharmaceutical partner’s growing drug-delivery platform. The expansion is 140,000 square feet of Class 8 cleanrooms designed for manufacturing, automation and assembly of drug-delivery devices. Phase One of the facility build includes more than 100 injection-molding machines, custom automation technology, and automated assembly lines. Phase Two builds on that foundation by doubling production capacity to support long-term product line growth.
Source: MGS
Appointments
Experic Appoints New CEO
Experic has announced the appointment of Matthew Mollan, Ph.D., currently Vice President, Operations, Early Phase at Catalent, as Chief Executive Officer (CEO). He will succeed David Wood, who will retire as CEO after five years of leadership at Experic.
Dr. Mollan joins Experic after more than three decades in leadership positions with pharmaceutical development and manufacturing organizations. Most recently, he served as Vice President, Operations, Early Phase at Catalent, where he managed a four-site development and small-scale commercial manufacturing network in the US and UK. Previously, he was General Manager of Catalent Drug Delivery Solutions, where he led a 500-person site. Earlier in his career, he held senior leadership roles at Aptuit and Pfizer, directing pharmaceutical development, clinical manufacturing, and formulation organizations.
Source: Experic
